Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: A systematic review

Thyroid

Volumn 22, Issue 9, 2012, Pages 918-925

  Soelberg, Kerstin Kathrine ^a   Bonnema, Steen Joop ^a   Brix, Thomas Heiberg ^a   Hegedüs, Laszlo ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

FOLLOW UP; HUMAN; HYPERMETABOLISM; LYMPHOMA; MAXIMUM STANDARDIZED UPTAKE VALUE; ONCOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; REVIEW; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID INCIDENTALOMA; THYROID MEDULLARY CARCINOMA; THYROID METASTASIS; THYROID NODULE; THYROID PAPILLARY CARCINOMA;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENTAL FINDINGS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS;

EID: 84865578806     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0005     Document Type: Review

References (37)

1. Hegedus L 2004 Clinical practice. The thyroid nodule. N Engl J Med 351:1764-1771.
2. Hegedus L, Bonnema SJ, Bennedbaek FN 2003 Management of simple nodular goiter: current status and future perspectives. Endocr Rev 24:102-132.
3. Dean DS, Gharib H 2008 Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab 22:901-911.
4. Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM, Moley JF 2001 Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 130:941-946.
5. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK 2005 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 115:1074-1078.
6. Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, Baek CH, Chung JH, Lee KH, Kim BT 2006 Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 47:609-615.
7. Chu QD, Connor MS, Lilien DL, Johnson LW, Turnage RH, Li BD 2006 Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 72:272-275.
8. Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, Jeong SY, Kim SW 2003 Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88:4100-4104.
9. Ohba K, Nishizawa S, Matsushita A, Inubushi M, Nagayama K, Iwaki H, Matsunaga H, Suzuki S, Sasaki S, Oki Y, Okada H, Nakamura H 2010 High incidence of thyroid cancer in focal thyroid incidentaloma detected by 18F-fluorodeoxyglucose [corrected] positron emission tomography in relatively young healthy subjects: results of 3-year follow-up. Endocr J 57:395-401.
10. Pagano L, Sama MT, Morani F, Prodam F, Rudoni M, Boldorini R, Valente G, Marzullo P, Baldelli R, Appetecchia M, Isidoro C, Aimaretti G 2011 Thyroid incidentaloma identified by (18)F-fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT): clinical and pathological relevance. Clin Endocrinol (Oxf) 75:528-534.
11. Kayani I, Groves AM 2006 18F-fluorodeoxyglucose PET/CT in cancer imaging. Clin Med 6:240-244.
12. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, Jaeger U 2006 Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47:616-624.
13. Zhuang H, Alavi A 2002 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32:47-59.
14. Eloy JA, Brett EM, Fatterpekar GM, Kostakoglu L, Som PM, Desai SC, Genden EM 2009 The significance and management of incidental [18F]fluorodeoxyglucose- positronemission tomography uptake in the thyroid gland in patients with cancer. AJNR Am J Neuroradiol 30:1431-1434.
15. Nishimori H, Tabah R, Hickeson M, How J 2011 Incidental thyroid "PETomas": clinical significance and novel description of the self-resolving variant of focal FDG-PET thyroid uptake. Can J Surg 54:83-88.
16. Salvatori M, Melis L, Castaldi P, Maussier ML, Rufini V, Perotti G, Rubello D 2007 Clinical significance of focal and diffuse thyroid diseases identified by (18)F-fluorodeoxyglucose positron emission tomography. Biomed Pharmacother 61:488-493.
17. Chen W, Parsons M, Torigian DA, Zhuang H, Alavi A 2009 Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun 30:240-244.
18. Are C, Hsu JF, Schoder H, Shah JP, Larson SM, Shaha AR 2007 FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol 14:239-247.
19. Hsieh H, Lin S, Yang B, Chu Y, Chang C, Liu R 2003 The clinical relevance of thyroid incidentalomas detected by 18Ffluorodeoxyglucose positron emission tomography. Ann Nucl Med Sci 16:53-58.
20. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, Kasperbauer JL, Strome SE, Reading CC, Hay ID, Lowe VJ 2007 The value of quantifying 18FFDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 28:373-381.
21. King DL, Stack BC Jr, Spring PM, Walker R, Bodenner DL 2007 Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg 137:400-404.
22. Kim BH, Na MA, Kim IJ, Kim SJ, Kim YK 2010 Risk stratification and prediction of cancer of focal thyroid fluorodeoxyglucose uptake during cancer evaluation. Ann Nucl Med 24:721-728.
23. Even-Sapir E, Lerman H, Gutman M, Lievshitz G, Zuriel L, Polliack A, Inbar M, Metser U 2006 The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 33:541-552.
24. Ishimori T, Patel PV, Wahl RL 2005 Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 46:752-757.
25. Chen YK, Ding HJ, Chen KT, Chen YL, Liao AC, Shen YY, Su CT, Kao CH 2005 Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 25:1421-1426.
26. Kwak JY, Kim EK, Yun M, Cho A, Kim MJ, Son EJ, Oh KK 2008 Thyroid incidentalomas identified by 18F-FDG PET: sonographic correlation. AJR Am J Roentgenol 191:598-603.
27. Bae JS, Chae BJ, Park WC, Kim JS, Kim SH, Jung SS, Song BJ 2009 Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer.World J SurgOncol 7:63.
28. Zhai G, Zhang M, Xu H, Zhu C, Li B 2010 The role of 18Ffluorodeoxyglucose positron emission tomography/computed tomography whole body imaging in the evaluation of focal thyroid incidentaloma. J Endocrinol Invest 33:151-155.
29. Kang BJ, JH O, Baik JH, Jung SL, Park YH, Chung SK 2009 Incidental thyroid uptake on F-18 FDG PET/CT: correlation with ultrasonography and pathology. Ann Nucl Med 23: 729-737.
30. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
31. National Cancer Institute. Available at http://seer.cancer.gov/csr/1975- 2008/sections.html (accessed on December 14, 2011).
32. Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, Peller PJ, Bahn RS, Lowe VJ 2007 Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 48:896-901.
33. Mitchell JC, Grant F, Evenson AR, Parker JA, Hasselgren PO, Parangi S 2005 Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. Surgery 138:1166-1174.
34. Van den BA, Maes A, De PT, Mortelmans L, DrijkoningenM, Van DB, Delaere P, Bouillon R 2002 Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 87: 1517-1520.
35. Ciampi R, Vivaldi A, Romei C, Del GA, Salvadori P, Cosci B, Pinchera A, Elisei R 2008 Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol 291:57-62.
36. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
37. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, Miyauchi A 2003 An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381-387.